Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tatiana A Ozharovskaya"'
Autor:
Inna V. Dolzhikova, Amir I. Tukhvatulin, Daria M. Grousova, Ilya D. Zorkov, Marina E. Komyakova, Anna A. Ilyukhina, Anna V. Kovyrshina, Artem Y. Shelkov, Andrey G. Botikov, Ekaterina G. Samokhvalova, Dmitrii A. Reshetnikov, Andrey E. Siniavin, Daria M. Savina, Dmitrii V. Shcheblyakov, Fatima M. Izhaeva, Alina S. Dzharullaeva, Alina S. Erokhova, Olga Popova, Tatiana A. Ozharovskaya, Denis I. Zrelkin, Polina P. Goldovskaya, Alexander S. Semikhin, Olga V. Zubkova, Andrey A. Nedorubov, Vladimir A. Gushchin, Boris S. Naroditsky, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Vaccines, Vol 12, Iss 10, p 1152 (2024)
Background: The SARS-CoV-2 virus continuously acquires mutations, leading to the emergence of new variants. Notably, the effectiveness of global vaccination efforts has significantly declined with the rise and spread of the B.1.1.529 (Omicron) varian
Externí odkaz:
https://doaj.org/article/5ca4e161630e45b996f7587289d1a662
Autor:
Dmitry V. Shcheblyakov, Ilya Gordeychuk, I. M. Evgrafova, Ilias B Esmagambetov, Ya V. Simakova, D. Yu. Logunov, P. G. Deryabin, Anna V. Kovyrshina, Borisevich Sv, M. V. Balyasin, Daria M. Grousova, A. I. Tukhvatulin, Botikov Ag, S. A. Gulyaev, L. V. Panina, Inna V. Dolzhikova, Elizaveta A. Tokarskaya, Boris S. Naroditsky, A L Gintsburg, Tatiana A Ozharovskaya, Olga V. Zubkova, Oksana E. Popova
Publikováno v:
Immunologiya. 41:135-143
Introduction Middle East respiratory syndrome (MERS) is acute inflammatory disease of respiratory system with a high mortality, caused Ьу coronavirus MERS-CoV At present moment, we still lack specific therapeutic preparations and vaccines against M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::393562fd6f085cfa839bfd143a5db6fa
https://doi.org/10.33029/0206-4952-2020-41-2-135-143
https://doi.org/10.33029/0206-4952-2020-41-2-135-143
Autor:
D. A. Kleymenov, Anna V. Kovyrshina, Nadezhda L. Lubenets, Natalia A. Nikitenko, Sergei V. Borisevich, Alexander S. Semikhin, Elizaveta A. Tokarskaya, Daria M. Grousova, Andrey Pochtovyi, M M Shmarov, Dmitry V. Shcheblyakov, Olga Popova, Shchetinin Am, Tatiana A Ozharovskaya, Andrey Komissarov, Evgeniia N. Bykonia, Alina S. Dzharullaeva, Dmitry Lioznov, Alexander L. Gintsburg, Artem P. Tkachuk, A. I. Tukhvatulin, Denis Y. Logunov, Nadezhda P. Kuznetsova, Liubov I. Popova, Olga V. Zubkova, Inna V. Dolzhikova, Lyudmila Vasilchenko, Elena V. Shidlovskaya, Alina S. Erokhova, E. P. Mazunina, Boris S. Naroditsky, Alexander Tsybin, Elizaveta V. Divisenko, Vladimir A. Gushchin, Daria Danilenko, Fatima M. Izhaeva
ObjectivesVaccination remains the most effective response to the COVID-19 pandemic. Most vaccines use two-dose regimens. In turn, single-dose vaccines also have high potential, since, on the one hand, they simplify the vaccination program, make it mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f145807fe93e4a55dadded1a8a6b758
https://doi.org/10.1101/2021.10.08.21264715
https://doi.org/10.1101/2021.10.08.21264715
Autor:
A. I. Tukhvatulin, Fatima M. Izhaeva, Denis Y. Logunov, Daria A. Egorova, Daria M. Grousova, Andrei G. Botikov, Alina S. Dzharullaeva, Sergei V. Borisevich, Olga Popova, Denis I. Zrelkin, Ilias B Esmagambetov, Alexander S. Semikhin, Daria V Voronina, Elena A Smolyarchuk, Dmitry N. Shcherbinin, Olga V. Zubkova, Nadezhda L. Lubenets, M M Shmarov, Anna V. Kovyrshina, Tatiana A Ozharovskaya, Boris S. Naroditsky, Dmitry V. Shcheblyakov, Inna V. Dolzhikova, Alexander L. Gintsburg, Irina A Favorskaya, Alina S. Erokhova, Natalia A. Nikitenko, Vladimir A. Gushchin, Sergey Zyryanov, Yana V. Simakova, Elizaveta A. Tokarskaya
Publikováno v:
The Lancet
Lancet (London, England)
Lancet (London, England)
Background A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials. Here, we report preli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45be4c8958b8b211911b441dc840d66e
Autor:
K. V. Zhdanov, N. V. Boyarskaya, A. F. Andrus, A A Lysenko, Alexander L. Gintsburg, Tatiana A Ozharovskaya, I. G. Rumyantseva, A. I. Tukhvatulin, Boris S. Naroditsky, D. A. Kutaev, N. M. Tukhvatulina, V. B. Pantyukhov, Petya G. Gancheva, Elizaveta A. Tokarskaya, Borisevich Sv, I V Shatokhina, A. N. Bel'skih, B. V. Belugin, Alexey V. Kostarnoy, Maxim M. Shmarov, Daria A. Egorova, Alina S. Dzharullaeva, S. M. Zakharenko, A. N. Voytyuk, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, S. I. Syromyatnikova, L. V. Kolobukhina, Denis Y. Logunov, Yana V. Simakova, S. V. Volchikhina, Olga V. Zubkova, V. F. Babira, T. V. Sizikova, D N Scherbinin, I. L. Tutykhina
Publikováno v:
Human Vaccines & Immunotherapeutics
Ebola hemorrhagic fever, also known as Ebola virus disease or EVD, is one of the most dangerous viral diseases in humans and animals. In this open-label, dose-escalation clinical trial, we assessed the safety, side effects, and immunogenicity of a no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::673f070445acfe3074bb02d8bac944b7
http://europepmc.org/articles/PMC5360131
http://europepmc.org/articles/PMC5360131
Autor:
Tatiana A Ozharovskaya, Nadezhda L. Lubenets, Sergei V. Borisevich, Alexander S. Semikhin, Daria M. Grousova, Andrei G. Botikov, Yana V. Simakova, Fatima M. Izhaeva, Alina S. Erokhova, Denis I. Zrelkin, Olga V. Zubkova, Irina A Favorskaya, Elena A Smolyarchuk, Boris S. Naroditsky, M M Shmarov, Natalia A. Nikitenko, Alina S. Dzharullaeva, Alexander L. Gintsburg, Morozova Lf, Daria A. Egorova, Evgeny V Kryukov, Dmitry V. Shcheblyakov, Olga Popova, Denis Y. Logunov, Dmitry N. Shcherbinin, Inna V. Dolzhikova, Amir I Tukhvatullin, Elizaveta A. Tokarskaya, Ilias B Esmagambetov, Vladimir F Babira, Anna V. Kovyrshina, Daria V Voronina
Publikováno v:
Yana Simakova
Lancet (London, England)
The Lancet
Lancet (London, England)
The Lancet
Summary Background We developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b04ada67ad427528778d88936c6006e